Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.
You may also be interested in...
340B Exemptions Offer Manufacturers ‘Significant’ Incentives To Seek Orphan Status – HHS OIG
Office of Inspector General report explores the orphan drug status of a set of blockbuster drugs with the highest level of spending in Medicare.
Drug Costs Not A Primary Driver Of Rare Disease Economic Burden
EveryLife Foundation study finds inpatient and outpatient care, not prescription drugs, are the primary excess medical costs associated with rare diseases.
The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.